PHARM Connect Congress is the largest and most important pharmaceutical and biotechnology business summit in the Central Eastern European region, taking place annually in March in Budapest, Hungary. With its 500+ participants from over 20 countries in the region and beyond, the Congress – to be held for the ninth time on 12-13 March 2019 – is a great platform to benchmark and network with an exclusive group of senior peers. We are here to help and accelerate the effectiveness of your marketing strategies, maximise ROI and stay ahead of the competition.


UP-TO-DATE MARKET INSIGHTS

In order to ensure the quality of the conference programme, we work closely together with leading local and regional associations, European and global media partners and our Programme Advisory Committee, whose members are well-known pharmaceutical and biopharmaceutical industry experts of leading international companies. The conference programme offers the most up-to-date market insights into research and development, production, engineering, supply chain and quality management related topics.

NETWORKING OPPORTUNITIES

Our event presents a unique opportunity to establish and develop fruitful, long-term and valuable business relations. Leading service providers of the pharmaceutical and biotechnology sector – covering a wide range of profiles from API’s and contract manufacturing to processing, biopharma solutions, biopharmaceuticals and biologicals, drug delivery systems, clean rooms, laboratory equipment, monitoring & inspection systems, quality control, packaging and labelling, automation, plant engineering and maintenance, logistics, cold chain storage and distribution, warehousing and many others – have the opportunity to meet the key decision makers of their targeted companies.

RETURN ON INVESTMENT

At TEG, we understand how challenging it is to find the right person, from each company at a time when they are ready to invest.

We are experts in supporting companies to increase their ROI, reducing sales cycles and accelerating the time-to-market.

PHARM Connect invites only senior decision makers with a purchasing power who are looking to invest into new services and solutions.

 


PROGRAMME ADVISORY COMMITTEE 2018

Dr Erik Bogsch
Dr Erik Bogsch

Head of the Biotechnology R&D Division


Dr Erik Bogsch

Dr Erik Bogsch

Head of the Biotechnology R&D Division, Gedeon Richter 

Dr Erik Bogsch is the Head of the Biotechnology R&D Division at Gedeon Richter Plc. He is responsible for leading the R&D effort in the development of GR's biosimilar pipeline. Gedeon Richter Plc. is engaged in the development and manufacture of both bacterial cell fermentation based and mammalian cell fermentation based biosimilar products. GR has R&D, analytical & manufacturing capabilities in multiple locations in Hungary & Germany.

Dr Bogsch, a Hungarian national, has a Natural Sciences degree from the University of Cambridge and a PhD in cell biology from the University of Warwick. Following a brief postdoctoral academic research career, he worked in the food industry for many years in R&D, Quality & Manufacturing roles in the UK, Hungary & Germany. He joined Gedeon Richter Plc. in 2012, as commissioning lead for GR's biotechnology factory in Debrecen, Hungary, before moving into his current role.

Marek Cichocki
Marek Cichocki

Head of Operational R&D


Marek Cichocki

Marek Cichocki

Head of Operational R&D, Polpharma

Marek Cichocki has been working in pharmaceutical industry for 13 years. He is an R&D expert with special focus on solid oral dosage forms development and manufacturing. Marek’s professional specialization includes: formulation design, scale-up and technology transfer activities, process validation, and new manufacturing methods.

Marek started his career in 2005 in Pliva Kraków (Poland) where he was a Formulation Scientist. From the beginning of 2010 Marek spent almost 4 years at Synthon BV (The Netherlands) being responsible for the implementation of newly developed products at Contract Manufacturing Organisations.  In February 2014 Marek joined Polpharma (Poland) and became Head of Formulation Development team. Currently he is holding a position of Head of Operational R&D and his main responsibilities are: post-approval product maintenance, technology transfers, R&D support for industrial operations and new technologies implementation.

Christopher Hunley
Christopher Hunley

Site Head and Managing Director


Christopher Hunley

Christopher Hunley

Site Head and Managing Director, GSK Biologicals Kft.

Chris is the Site Director at the GSK Biologicals Kft. Vaccine manufacturing facility in Gödöllő.  He joined the site in 2015, after 5 years working in Italy and Germany with Novartis Vaccines. Before moving into the vaccines business, he spent several years working for Amgen in the United States on the manufacturing of various bulk biologics.  Chris is a chemical engineer, who has spent his career working in manufacturing facilities with roles in Manufacturing, Validation, Project Management, and Manufacturing Sciences & Technology.

Dr Piotr Lipiński
Dr Piotr Lipiński

Quality Systems Manager


Dr Piotr Lipiński

Dr Piotr Lipiński

Quality Systems Manager/QP, Novartis Technical Operations-Platform Solids Europe, Lek / Novartis

Piotr has over 10 years of experience in pharmaceutical companies. Currently he is Quality Systems Manager and Qualified Person in Novartis Technical Operation in Poland.

The experience includes particularly scope quality systems implementation, self-inspections, trainings and auditing of materials, products suppliers and service providers. Piotr has detailed knowledge in scope of all GxP rules with special focus on Good Manufacturing Practice and Good Distribution Practice.

Piotr is a PhD Eng. in scope of Technology of Chemistry. Additionally, he completed post-graduate studies in scope of Industrial Chemistry at Medical University of Gdansk. He was participating as well in numerous courses related to GMP aspects in pharmaceutical industry.

Dr Zsolt Holló
Dr Zsolt Holló

Head of the Center of Biological Business Development and Technology


Dr Zsolt Holló

Dr Zsolt Holló

Head of the Center of Biological Business Development & Technology, Egis Gyógyszergyár Zrt.

Dr Holló is medical doctor by training, obtained his PhD in cellular physiology at Semmelweis University (Budapest) and MBA degree at the Budapest University of Technology and Economics. Dr Holló has over 10 years experience in biotechnology. Currently he is Head of the Biological Business Development and Technology Center at EGIS Pharmaceuticals Plc. His major responsibilities include biosimilar product-candidate evaluations; the implementation of biosimilar product related manufacturing and analytical technologies, quality control, management of  technology transfers; developing partnerships in these areas.

Prior to this position he was Chief Operations Officer at Solvo Biotechnology. He has spent more than 5 years in molecular diagnostics, in various positions from laboratory head to CEO. He has worked in the Netherlands Cancer Institute as an EMBO postdoctoral fellowship holder. Dr Holló has several publications and patents in cellular signalling, multidrug resistance and molecular diagnostics.

Lenka Francišković
Lenka Francišković

Head of Processes and Products Quality


Lenka Francišković

Lenka Francišković

Head of Processes and Products Quality, Belupo Pharmaceuticals

Lenka is a Pharmaceutical Professional with a unique combination of pharmaceutical management experience and exceptional knowledge in the areas of the New Product Evaluation, Laboratory Operations, Pharmaceutical Analysis and Project Management. She has an extensive experience in pharmaceutical industry in Research and Development, Regulatory Affairs, Quality Assurance and Quality Control Environment as well as profound knowledge of TPB and FDA, EU and Croatian regulatory submission requirements.

Strong knowledge of GMP, GLP, ICH guidelines and Pharmacopoeia is inevitable part of Lenkas‘ professional skills. Lenka is currently Head of Processes and Products Quality for Belupo Pharmaceuticals Croatia. Prior to this work, she worked in several positions at Apotex Inc. Toronto, Ontario and Genpharm Inc. (now Milan Pharmaceuticals) in Etobicoke, Ontario. Lenka has published several publications, is member of Pharmaceutical Sciences Group, Toronto and Croatian Association for Quality.

István Király
István Király

VP - Site Director Siena & Rosia Operations


István Király

István Király

VP, Site Director Siena & Rosia Operations, GSK Vaccines 

István Király graduated from the Technical University in Budapest as a mechanical engineer. During his professional career he has filled several technical- and production-related management positions in different industries at large international companies such as General Electric, DANONE, Alcoa and GlaxoSmithKline.

These challenges allowed him to be involved in the implementation and operation of different management and quality systems such as ISO, HACCP, GMP, Toyota Production System, Six Sigma and Lean Sigma. In 2006 he joined  GSK Vaccines and started his career in Gödöllő Manufacturing site. He held various senior management positions until he was appointed as Managing director of the site in 2011. Between September 2015 and June 2016 he was Head of Operations of the legacy Novartis Vaccines sites, overseeing the industrial operations of those sites and also managing the integration of those newly acquired manufacturing units into GSK Vaccines industrial network.

In June 2016 István was promoted to his current position as VP, Site Director Siena & Rosia Operations, Italy at GSK Vaccines.  

Dr Sergii Sur
Dr Sergii Sur

Regulatory Affairs Director


Dr Sergii Sur

Dr Sergii Sur

Regulatory Affairs Director, Arterium Corporation

Dr Sur has over 25 years of work experience in the pharmaceutical market, including 14 years in management positions. He received his PhD degree in Pharmacy and published approximately 100 scientific publications. Between 1993 and 1998 he was the Head of State Laboratory for Quality Control of Medicines at the Institute of Pharmacology and Toxicology at the Ukrainian Academy of Medical Sciences in Kiev.

Between 1998 and 2005 he worked for the Ukraine Ministry of Health, firstly as the Director of Central Laboratory for Quality Control of Medicines and since 2000 as the Deputy Chief Inspector for Quality Control of Medicines. Since 2005, Dr Sur has been in his current position responsible for the development of a functional strategy in R&D; the development and introduction of R&D business processes and structure; and the organisation of research, development and registration of new products.

Additionally, Dr Sur is a member of the International Federation of Pharmacists (FIP) and since 1998 has been an adviser on International Pharmacopoeia and Pharmaceutical Preparations and since 2002 also on Traditional Medicines for the WHO which is headquartered in Geneva.

Prof Dr Stane Srčič
Prof Dr Stane Srčič

Head of Pharmaceutical Technology Department


Prof Dr Stane Srčič

Prof Dr Stane Srčič

Head of Pharmaceutical Technology Department, Faculty of Pharmacy, University of Ljubljana

Dr Stane Srčič is a Professor for Pharmaceutical Technology at the Faculty of Pharmacy, University of Ljubljana, Slovenia. His expertise is focused on solid oral dosage forms development and manufacturing and includes pre-formulation and  formulation, new manufacturing methods and customized equipment. After PhD he spent as post doc at the University of Regensburg, and was/is acting as a visiting Professor at the University of Liverpool, Szeged and Sarajevo. He served for more than 10 years as an expert from Slovenia on EMA (London) in the Committee for drugs in veterinary medicines and was responsible for quality parts of the dossiers.

He published more than 150 papers and is holder of  numerous patents and patents applications in EU, US, Russian Federation and India. He is strongly connected with domestic and foreign pharmaceutical industry and was leading a lot of different academia-industry projects.

His international collaboration on the education and research areas has been recognized and awarded with the honorary doctorate from the University of Szeged (Hungary).

Dr András Ballagi
Dr András Ballagi

CTO


Dr András Ballagi

Dr András Ballagi

CTO, Diagon

Dr Ballagi moved to Sweden shortly after completing his degree in Bioengineering. There he worked in the field of the diagnosis and molecular evolution of veterinary viruses at the Swedish Veterinary Institute. He received his PhD for his research on application of PCR for virus detection and analysis of viral outbreaks. Later he moved on to fermentation technology of recombinant microorganisms at the University of Uppsala. After almost 20 years in Sweden he returned to Hungary in 2006 and joined Gedeon Richter Plc. to lead the technology development for biosimilar medicine production using bacteria (E.coli) as well as mammalian (CHO) cells.

In 2014 he formed the Biotechnology unit in the newly established Pharmatech Model Laboratory (PML) at the Budapest University of Technology and Economics, where he is also holding an Honorary Professorship. Since November 2016 he responsible for the recombinant protein development and production of human diagnostic at the Diagon Ltd, Budapest. 

VENUE AND LOCATION

ABOUT HUNGARY

Hungary is one of the largest and most developed drug markets in Central Eastern Europe. Large international pharmaceutical companies are among those that have invested in local manufacturing, as well as early and late stage R&D. In addition Hungary boasts the strongest biotech sector of the 14 new EU member states. 

ABOUT THE LOCATION

Budapest is a city of full of surprises and wonder, with its lively centre, pretty parks, majestic river, tall church spires and lavish spas. One of the most exciting cities in the world, Budapest is full of secrets, hidden spots to explore and old favourites to revisit. This is the city where being bored is not an option. Experience it yourself in the Budapest Congress Centre, the largest, most modern congress and meeting facility in Hungary. The Novotel Budapest City connected to the Budapest Congress Centre offers 319 new Novation rooms.